Abstract
According to the National Cancer Institute (INCA) breast cancer is the most common cancer among women in the world; in 2020, 2.3 million new cases were estimated. Regarding treatment, it is known that the use of PARP1 inhibitors (Poly (ADP-ribose) Polymerase 1) for individuals with a BRCA1/2 mutation is a relevant therapeutic strategy based on synthetic lethality. S6K1/2 proteins mediate …